These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


583 related items for PubMed ID: 19929036

  • 1. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L, Iannazzo S, Zaniolo O.
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [Abstract] [Full Text] [Related]

  • 2. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 3. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG, Cerulli A, Frech FH.
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 5. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
    Baker TM, Goh J, Johnston A, Falvey H, Brede Y, Brown RE.
    J Med Econ; 2012 Oct 20; 15(2):253-60. PubMed ID: 22084957
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 20; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 8. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
    Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, Ingrillì F, Pettinati G, Glazer R, Tognoni G, Cohn J.
    Int J Cardiol; 2007 Jun 25; 119(1):48-53. PubMed ID: 17049646
    [Abstract] [Full Text] [Related]

  • 9. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug 25; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 10. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
    Taylor M, Scuffham PA, Chaplin S, Papo NL.
    Value Health; 2009 Jun 25; 12(4):459-65. PubMed ID: 19192258
    [Abstract] [Full Text] [Related]

  • 11. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG.
    Eur Heart J; 2007 Jan 25; 28(1):42-51. PubMed ID: 17110403
    [Abstract] [Full Text] [Related]

  • 12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec 25; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 13. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun 25; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 14. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.
    Am Heart J; 2004 Dec 25; 148(6):951-7. PubMed ID: 15632877
    [Abstract] [Full Text] [Related]

  • 15. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis.
    Perez A, Touchette DR, DiDomenico RJ, Stamos TD, Walton SM.
    Pharmacotherapy; 2011 Jun 25; 31(6):552-65. PubMed ID: 21923439
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A, Barberà JA, Escribano P, Sala ML, Febrer L, Oyagüez I, Sabater E, Casado MA.
    Appl Health Econ Health Policy; 2012 May 01; 10(3):175-88. PubMed ID: 22452448
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C, Mealing S, Hawkins N, Eaton J, Brown B, Daubert JC, REVERSE study group.
    Eur Heart J; 2011 Jul 01; 32(13):1631-9. PubMed ID: 21112898
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, Clapp-Channing NE, Davidson-Ray L, Poole JE, Johnson G, Anderson J, Lee KL, Bardy GH, SCD-HeFT Investigators.
    Circulation; 2006 Jul 11; 114(2):135-42. PubMed ID: 16818817
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Jul 11; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 20. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
    Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators.
    Circulation; 2005 Sep 06; 112(10):1428-34. PubMed ID: 16129801
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 30.